Astellas Pharma
4503.T4503.T · Stock Price
Historical price data
Overview
Astellas Pharma is a Japan-based global pharmaceutical leader with a mission to deliver transformative therapies in areas of high unmet medical need. Formed by the 2005 merger of Yamanouchi and Fujisawa, the company has grown into a $45.8 billion market cap entity with a vertically integrated model spanning R&D, manufacturing, and global commercialization. Its strategy is anchored in a patient-centric approach, a robust pipeline, and strategic external innovation to drive growth in core therapeutic areas and next-generation modalities.
Technology Platform
Astellas employs a modality-agnostic suite of next-generation platforms including Targeted Protein Degradation (PROTACs), Cell & Gene Therapies, Immuno-Oncology, Antibody-Drug Conjugates (ADCs), and Genetic Regulation, complemented by digital health initiatives (Rx+).
Pipeline
200| Drug | Indication | Stage | Watch |
|---|---|---|---|
| Prograf-XL + Prograf + MMF | Liver Transplantation | Phase 3 | |
| Enzalutamide + Placebo | Castration-Resistant Prostate Cancer | Phase 3 | |
| micafungin + amphotericin B deoxycholate | Candidiasis | Phase 3 | |
| micafungin + fluconazole + liposomal amphotericin B + caspof... | Liver Transplantation | Phase 3 | |
| ipragliflozin | Type 2 Diabetes Mellitus | Phase 3 |
Funding History
1FDA Approved Drugs
19Opportunities
Risk Factors
Competitive Landscape
Astellas competes with global pharma giants (Roche, Merck, BMS) in oncology and specialized players in rare diseases. Its differentiation relies on biomarker-driven approaches, novel modalities like protein degraders, and a global commercial footprint. Success hinges on outperforming peers in clinical innovation and execution.
Company Timeline
Founded in Tokyo, Japan
Initial Public Offering
FDA Approval: IZERVAY
FDA Approval: VEOZAH
FDA Approval: VYLOY